These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Stockmeyer B; Berens C; Oduncu FS; Mackensen A; Fey GH MAbs; 2012; 4(1):45-56. PubMed ID: 22327429 [TBL] [Abstract][Full Text] [Related]
5. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837 [TBL] [Abstract][Full Text] [Related]
6. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437 [TBL] [Abstract][Full Text] [Related]
7. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
8. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells. Schiller CB; Braciak TA; Fenn NC; Seidel UJ; Roskopf CC; Wildenhain S; Honegger A; Schubert IA; Schele A; Lämmermann K; Fey GH; Jacob U; Lang P; Hopfner KP; Oduncu FS Oncotarget; 2016 Dec; 7(50):83392-83408. PubMed ID: 27825135 [TBL] [Abstract][Full Text] [Related]
9. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL. Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302 [TBL] [Abstract][Full Text] [Related]
10. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64). Chen J; Zhou JH; Ball ED Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927 [TBL] [Abstract][Full Text] [Related]
11. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450 [TBL] [Abstract][Full Text] [Related]
12. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies. Zugmaier G; Klinger M; Schmidt M; Subklewe M Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042 [TBL] [Abstract][Full Text] [Related]
13. T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Roskopf CC; Schiller CB; Braciak TA; Kobold S; Schubert IA; Fey GH; Hopfner KP; Oduncu FS Oncotarget; 2014 Aug; 5(15):6466-83. PubMed ID: 25115385 [TBL] [Abstract][Full Text] [Related]
14. [Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia]. Lin ZK; Zhang R; Ge Z; Liu J; Wu YJ; Guo X; Qiao C; Qiu HR; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):289-95. PubMed ID: 23628018 [TBL] [Abstract][Full Text] [Related]
15. Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. Kloess S; Ede Valverde da Silva A; Oberschmidt O; Gardlowski T; Matthies N; Vyas M; Arseniev L; Heuser M; Pogge von Strandmann E; Köhl U Front Immunol; 2017; 8():1100. PubMed ID: 28943878 [TBL] [Abstract][Full Text] [Related]
16. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Kellner C; Bruenke J; Horner H; Schubert J; Schwenkert M; Mentz K; Barbin K; Stein C; Peipp M; Stockmeyer B; Fey GH Cancer Lett; 2011 Apr; 303(2):128-39. PubMed ID: 21339041 [TBL] [Abstract][Full Text] [Related]
17. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens]. Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339 [TBL] [Abstract][Full Text] [Related]
18. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000 [TBL] [Abstract][Full Text] [Related]
19. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596 [TBL] [Abstract][Full Text] [Related]
20. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]